Search - tctmd.com

Displaying 381 - 400 of 678

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2019

Caitlin E. Cox

January 31, 2019

News Conference News ISET 2019

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

Caitlin E. Cox

January 30, 2019

Presentation ISET 2019

VIRTUS: Trial Design adn Primary Endpoint Results

Presenter: Robert Lookstein

January 30, 2019

Presentation ISET 2019

5-Year Results from the IN.PACT SFA Randomized Trial

Presenter: Gary Ansel

January 30, 2019

Presentation ISET 2019

Drug-Coated Therapy for ISR: Review of Options and Data

Presenter: Brian DeRubertis

January 30, 2019

News Conference News ISET 2019

Chelation for CLI in Diabetic Patients Shows Potential in Small Series

Caitlin E. Cox

January 29, 2019

News Conference News ISET 2019

Paclitaxel in PAD: What to Tell Patients While the Numbers Are Crunched

Caitlin E. Cox

January 28, 2019

News Conference News ISET 2019

PAD in the Spotlight: Awareness, Treatment Remain Low Despite Many Years of Research

Caitlin E. Cox

January 28, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Daily News

AAA Rupture Rate in England Supports Current Thresholds for Surveillance, Intervention—With Some Caveats

Shelley Wood

January 21, 2019

News Daily News

FDA Alerts Doctors to Potential Late Risks With Paclitaxel-Coated Balloons and Stents in PAD

Michael O'Riordan

January 17, 2019

News Daily News

Guidelines for Peripheral Interventions Often Built on Shaky Foundation

Caitlin E. Cox

January 10, 2019

News Features

Top News in Endovascular Therapy: 2018

L.A. McKeown

December 28, 2018

News Daily News

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

L.A. McKeown

December 17, 2018

News Daily News

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

L.A. McKeown

December 07, 2018

News Daily News

FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies

Michael O'Riordan

December 06, 2018

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

L.A. McKeown

November 15, 2018

News Conference News VIVA 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

L.A. McKeown

November 13, 2018

News Conference News VIVA 2018

Now You See Them, Now You Don’t: Bioresorbable Devices Target Large-Bore Closures and PE Prevention

L.A. McKeown

November 09, 2018

Advertisement

TCTMD’s Top 10 Most Popular Stories for January 2019

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

VIRTUS: Trial Design adn Primary Endpoint Results

5-Year Results from the IN.PACT SFA Randomized Trial

Drug-Coated Therapy for ISR: Review of Options and Data

Chelation for CLI in Diabetic Patients Shows Potential in Small Series

Paclitaxel in PAD: What to Tell Patients While the Numbers Are Crunched

PAD in the Spotlight: Awareness, Treatment Remain Low Despite Many Years of Research

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

AAA Rupture Rate in England Supports Current Thresholds for Surveillance, Intervention—With Some Caveats

FDA Alerts Doctors to Potential Late Risks With Paclitaxel-Coated Balloons and Stents in PAD

Guidelines for Peripheral Interventions Often Built on Shaky Foundation

Top News in Endovascular Therapy: 2018

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

Now You See Them, Now You Don’t: Bioresorbable Devices Target Large-Bore Closures and PE Prevention

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content